Prior treatment with anti?PD-1, or anti?PD-L1 therapeutic antibody or pathway-targeting agents
Prior treatment with CD137 agonists, anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway targeting agents
Prior treatment with anti-PD-1, CTLA-4, or anti-PD-L1 therapeutic antibody or pathway-targeting agents
Prior treatment with a CD137 agonists, anti-CTLA4 (except melanoma), anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway targeting agents
Prior treatment with anti?PD-1, or anti?PD-L1 therapeutic antibody or pathway targeting agents
Prior treatment with trastuzumab emtansine, cluster of differentiation 137 agonists, anti-programmed death-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents
Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway targeting agents
Prior treatment with anti-PD-1, and CTLA-4, or anti-PD-L1 therapeutic antibody or pathway-targeting agents
Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents
Prior treatment with anti-CTLA-4 therapeutic antibody or pathway-targeting agents
Prior treatment with CD137 agonists, anti-CTLA4, anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents
Prior exposure to immunotherapy (either as a single agent or in combination) including but not limited to CD137 or OX40 agonists, anti-CTLA-4, anti-PD-1, or anti-PD-L1, anti-PD-L2 antibody or pathway-targeting agents
Prior treatment with anti-PD-1, anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), or anti-PD-L1 therapeutic antibody or pathway-targeting agents
Prior treatment with CD137 agonists, anti- cytotoxic T-lymphocyte-associated protein 4, anti-PD-1, or anti-PDL1 therapeutic antibody or pathway targeting agents; prior IFN alpha or IL-2 is allowed following 4 week washout from treatment end date
Prior treatment with CD137 agonists, anti?PD-1, or anti?PD-L1 therapeutic antibody or pathway-targeting agents
Prior treatment with CD137 agonists, anti-CTLA-4, anti-programmed death-1 (PD-1), or anti-PD-L1 therapeutic antibody or pathway-targeting agents
